AstraZeneca extended its China drug-development footprint with a new pact with CSPC Pharmaceutical covering two kidney disease candidates. The deal includes a $30 million upfront payment and is structured around joint discovery and development. This follows AstraZeneca’s other recently disclosed collaboration with CSPC and underscores how large pharma is using China partners for therapeutic pipeline buildout. Kidney disease remains a high-need area for innovation, spanning fibrosis, CKD progression, and related complications. For CSPC, the agreement adds to its portfolio of strategic collaborations and may accelerate translation of early assets into clinical candidates.